US drug giant Merck & Co (NYSE: MRK) has signed a new non-exclusive agreement with Swiss major Roche (ROG: SIX) for the global promotion, upon appropriate marketing approvals, of Victrelis (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin (peg/riba).
Under the terms of the deal, Roche and Merck will work together in global markets, including Europe, Asia and Latin America, to educate physicians and patients about hepatitis C virus (HCV). The companies previously announced an agreement to promote Victrelis in the USA and collaborate to explore new treatment regimens for patients with chronic HCV, just days after the drug gained US Food and Drug Administration approval (The Pharma Letters May 16 and 18).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze